Clinical trial
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With…
NCT00073879 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00073879 |
|---|---|
| Title | Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation |
| Official title | Allogeneic Adoptive Immunochemotherapy For Treatment Of Renal Cell Carcinoma |
| Lead sponsor | Baylor College of Medicine, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | alemtuzumab, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation |
| Start date | Apr 1, 2003 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Dec 11, 2003 |
| Last update posted | Jan 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: